Creative Life Science Showcases PIC/S GMP-Compliant Cell Therapy Manufacturing Platform at BIO Asia-Taiwan 2026
核心洞察
Creative Life Science (搜索) reported record first-half 2026 revenue of NT$568 million, up 13.18% year-on-year, driven by regenerative medicine materials and services.
The company's 2,180-square-meter Zhubei facility is PIC/S GMP-compliant, featuring ISO Class 5 isolators and automated aseptic filling systems for cell therapy manufacturing.
Taiwan's new regenerative medicine laws, fully effective January 2026, are raising requirements for material traceability, aseptic manufacturing, and batch release testing.
TAIPEI — Creative Life Science (搜索) (7837) is positioning itself as a critical upstream partner for the cell and gene therapy industry, unveiling its PIC/S GMP-compliant biomanufacturing platform at BIO Asia-Taiwan 2026. The company's showcase, running July 16–19 at the Taipei Nangang Exhibition Center, highlights its expanding capabilities in GMP-grade culture media, process development, aseptic filling, and quality-control testing — services that are increasingly essential as regenerative medicines move from clinical translation toward commercialization.
The company reported cumulative revenue of NT$568 million for the first half of 2026, a 13.18% increase year-on-year and a record high for the period. Creative Life Science (搜索) has identified critical regenerative medicine materials, process services, and international partnerships as key growth drivers, building on its established portfolio of culture media, diagnostic reagents, and testing services.
Regulatory Tailwinds Reshape the Manufacturing Landscape
Taiwan's two landmark regenerative medicine laws and their implementing regulations — introduced progressively from 2025 and fully effective as of January 1, 2026 — are fundamentally raising the bar for manufacturers. The new framework imposes stricter requirements for material traceability, process scale-up, aseptic manufacturing, batch release, and analytical testing. These capabilities have become critical gateways to clinical development and market entry, creating both challenges for therapy developers and opportunities for qualified manufacturing partners.
Creative Life Science (搜索) supports the upstream regenerative medicine ecosystem with GMP-grade culture media, serum-free media, cryopreservation solutions, cell-process development, aseptic filling, and quality-control testing — a comprehensive suite designed to help customers accelerate the transition from R&D to clinical application.
Zhubei Facility: Infrastructure Built for Compliance
Located in the Hsinchu Biomedical Science Park, the company's 2,180-square-meter Zhubei facility is PIC/S GMP-compliant and incorporates ISO Class 5 isolators and automated aseptic filling systems. The quality management framework aligns with QMS/ISO 13485 principles, while laboratory capabilities are built around ISO/IEC 17025 standards. Services span process development and scale-up, research-use-only (RUO)-to-GMP conversion, technology transfer, aseptic filling, and quality testing.
International Engagement and Asia Expansion Strategy
In conjunction with BIO Asia-Taiwan, Creative Life Science (搜索) hosted the "2026 Taiwan Biotechnology Industry Delegation" on July 14. Organized by Taiwan's Overseas Community Affairs Council, the delegation brought together 21 overseas Taiwanese entrepreneurs and business leaders from 10 countries across four continents. Participants toured the cell culture media production line and product showcase areas, gaining first-hand insight into the company's capabilities.
Notably, delegation members included a CMC product development executive from Alnylam, a global leader in RNA interference therapeutics, and a global regulatory affairs director from AstraZeneca — underscoring the level of interest from multinational pharmaceutical companies in the company's manufacturing platform.
In late 2025, Creative Life Science (搜索) signed a cooperation agreement with Singapore-based ESCO (搜索), establishing a foundation for collaboration in Southeast Asia. The company plans to continue expanding its presence in Singapore, Japan, and other Asian markets, targeting regions where cell and gene therapy development is accelerating.
During BIO Asia-Taiwan, the company is hosting a seminar titled "From Standardization to Product Release: Critical Analytical Strategies for Regenerative Medicine Product Development" on July 17, covering process development, analytical methods, and product-release practices. Creative Life Science (搜索), currently registered on Taiwan's Emerging Stock Market, plans to apply for listing on the Taipei Exchange in the second half of 2026.